Vyriad Secures Final $25M Series B Tranche to Advance In Vivo CAR T Candidate into Clinic
ROCHESTER, Minn.–(BUSINESS WIRE)–Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, today announced the closing of the $25M final tranche to its Series B financing, bringing the total…